Please assess the completion status of the following clinical trial:

Trial Title: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age 18 and older~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman v2.0, Roche Diagnostics) with HCV RNA \> 800,000 IU/mL~* HCV genotype 1 (Inno-LiPA, Innogenetics)~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 gram per deciliter for men and \< 12 gram per deciliter for women)~* Neutropenia (neutrophil count \<1,500 per cubic milliliter)~* Thrombocytopenia (platelet \<90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 gram per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFPP and Peg-IFN + RBV (Type: EXPERIMENTAL): Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight \< 75 kg, 1,000 mg/day and body weight \>= 75 kg, 1,200 mg/day)
- Peg-IFN + RBV (Type: ACTIVE_COMPARATOR): Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight \< 75 kg, 1,000 mg/day and body weight \>=75 kg, 1,200 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).